WANTAI BIOLOGICAL(SH:603392) Ke Ji Ri Bao·2025-12-05 00:42Group 1 - The first domestically produced nine-valent HPV vaccine has been officially launched in Beijing, providing a new and economical option for women aged 9 to 45 in cervical cancer prevention [1] - The vaccine can effectively prevent over 70% of cervical cancer cases and reduce the incidence of other diseases caused by HPV infection [1] - The National Health Commission has included the HPV vaccine in the national immunization program, offering free vaccinations for girls aged 13 who were born after November 10, 2011 [1] Group 2 - The nine-valent HPV vaccine was developed by Xiamen University and Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., taking 18 years to complete [2] - Clinical trials involving over 11,000 healthy volunteers aged 9 to 45 have been conducted since 2019, demonstrating the vaccine's immunogenicity and safety comparable to imported products [2] - The vaccine is priced at 499 yuan per dose, with a total of 3 doses required for women aged 18 to 45, while those aged 9 to 17 only need 2 doses [2]